Mesoblast (NASDAQ:MESO) Shares Gap Up to $3.49

Mesoblast Limited (NASDAQ:MESO)’s share price gapped up before the market opened on Thursday . The stock had previously closed at $3.49, but opened at $4.46. Mesoblast shares last traded at $5.01, with a volume of 11,940,182 shares traded.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Mesoblast in a research report on Friday, January 12th. StockNews.com raised Mesoblast from a “sell” rating to a “hold” rating in a research report on Monday, March 4th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $13.67.

Mesoblast Price Performance

The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.95 and a current ratio of 2.71. The company has a market cap of $508.67 million, a P/E ratio of -3.75 and a beta of 3.44. The firm has a 50 day moving average price of $2.10 and a two-hundred day moving average price of $2.27.

Hedge Funds Weigh In On Mesoblast

A number of large investors have recently bought and sold shares of MESO. Lazari Capital Management Inc. grew its position in shares of Mesoblast by 9.3% in the 3rd quarter. Lazari Capital Management Inc. now owns 94,034 shares of the company’s stock worth $116,000 after buying an additional 8,000 shares during the last quarter. Prosperity Wealth Management Inc. purchased a new stake in Mesoblast in the third quarter worth $79,000. Wells Fargo & Company MN grew its stake in Mesoblast by 55.0% in the second quarter. Wells Fargo & Company MN now owns 52,813 shares of the company’s stock worth $206,000 after purchasing an additional 18,747 shares during the period. BlackRock Inc. grew its stake in shares of Mesoblast by 68.6% in the second quarter. BlackRock Inc. now owns 140,716 shares of the company’s stock worth $550,000 after acquiring an additional 57,252 shares during the last quarter. Finally, EWA LLC purchased a new stake in shares of Mesoblast in the first quarter worth $40,000. 1.43% of the stock is owned by hedge funds and other institutional investors.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.